Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.

EZH2 or EZH1 (enhancer of zeste homologue 2 or 1) is the catalytic subunit of polycomb repressive complex 2 (PRC2) that catalyzes methylation of histone H3 lysine 27 (H3K27). PRC2 hyperactivity and/or hypertrimethylation of H3K27 are associated with numerous human cancers, therefore inhibition of PRC2 complex has emerged as a promising therapeutic approach. Recent studies have shown that EZH2 and EZH1 are not functionally redundant and inhibition of both EZH2 and EZH1 is necessary to block the progression of certain cancers such as mixed-lineage leukemia (MLL)-rearranged leukemias. Despite the significant advances in discovery of EZH2 inhibitors, there has not been a systematic structure-activity relationship (SAR) study to investigate the selectivity between EZH2 and EZH1 inhibition. Here, we report our SAR studies that focus on modifications to various regions of the EZH2/1 inhibitor UNC1999 (5) to investigate the impact of the structural changes on EZH2 and EZH1 inhibition and selectivity.

[1]  Ryan D. Morin,et al.  Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin , 2010, Nature Genetics.

[2]  R. Willemze,et al.  The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma , 2001, British journal of haematology.

[3]  A. Good,et al.  Discovery, design, and synthesis of indole-based EZH2 inhibitors. , 2015, Bioorganic & medicinal chemistry letters.

[4]  P. Steigemann,et al.  EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes , 2015, Molecular Cancer Therapeutics.

[5]  Thomas Stützle,et al.  PLANTS: Application of Ant Colony Optimization to Structure-Based Drug Design , 2006, ANTS Workshop.

[6]  J. Bonanno,et al.  Structural Context of Disease-Associated Mutations and Putative Mechanism of Autoinhibition Revealed by X-Ray Crystallographic Analysis of the EZH2-SET Domain , 2013, PloS one.

[7]  Yan Liu,et al.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.

[8]  O. Elemento,et al.  EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. , 2010, Blood.

[9]  Yuquan Wei,et al.  Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer , 2016, Scientific Reports.

[10]  Stormy J. Chamberlain,et al.  The Murine Polycomb Group Protein Eed Is Required for Global Histone H3 Lysine-27 Methylation , 2005, Current Biology.

[11]  Xin Liu,et al.  Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2 , 2015, Science.

[12]  D. Reinberg,et al.  Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. , 2008, Molecular cell.

[13]  Gilles Marcou,et al.  Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints , 2007, J. Chem. Inf. Model..

[14]  P. Atadja,et al.  Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation , 2012, Proceedings of the National Academy of Sciences.

[15]  M. Scholfield,et al.  Halogen bonding (X‐bonding): A biological perspective , 2013, Protein science : a publication of the Protein Society.

[16]  Tim J. Wigle,et al.  Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 , 2013, Proceedings of the National Academy of Sciences.

[17]  J. Simon,et al.  Roles of the EZH2 histone methyltransferase in cancer epigenetics. , 2008, Mutation research.

[18]  S. Armstrong,et al.  Polycomb repressive complex 2 is required for MLL-AF9 leukemia , 2012, Proceedings of the National Academy of Sciences.

[19]  K. Hahn,et al.  An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. , 2013, ACS chemical biology.

[20]  D. Reinberg,et al.  Nucleosome-binding activities within JARID2 and EZH1 regulate the function of PRC2 on chromatin , 2013, Genes & development.

[21]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[22]  Yi Zhang,et al.  SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. , 2004, Molecular cell.

[23]  Kristian Helin,et al.  EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer , 2003, The EMBO journal.

[24]  Jian Jin,et al.  Chemical Probes of Histone Lysine Methyltransferases , 2014, ACS chemical biology.

[25]  C. Nislow,et al.  Mammalian homologues of the Polycomb‐group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S.cerevisiae telomeres , 1997, The EMBO journal.

[26]  M. Beringer,et al.  Role of PRC2‐associated factors in stem cells and disease , 2015, The FEBS journal.

[27]  O. Abdel-Wahab,et al.  The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.

[28]  W. L. Jorgensen,et al.  Methyl effects on protein-ligand binding. , 2012, Journal of medicinal chemistry.

[29]  D. Reinberg,et al.  Role of the polycomb protein EED in the propagation of repressive histone marks , 2009, Nature.

[30]  P. Trojer,et al.  EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation. , 2014, Chemistry & biology.

[31]  D. Reinberg,et al.  The Polycomb complex PRC2 and its mark in life , 2011, Nature.

[32]  A. Joerger,et al.  Principles and applications of halogen bonding in medicinal chemistry and chemical biology. , 2013, Journal of medicinal chemistry.

[33]  S. Merajver,et al.  Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. , 2006, Cancer research.

[34]  Kristian Helin,et al.  Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity , 2004, The EMBO journal.

[35]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[36]  S. Lowe,et al.  The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;NrasG12D acute myeloid leukemia , 2013, Oncogene.

[37]  K. Gajiwala,et al.  Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance , 2016, Nature Communications.

[38]  Tim J. Wigle,et al.  A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. , 2012, Nature chemical biology.

[39]  D. Reinberg,et al.  Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. , 2002, Genes & development.

[40]  A. P. Graves,et al.  Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. , 2012, ACS medicinal chemistry letters.

[41]  B. Garcia,et al.  Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. , 2014, Blood.

[42]  Jon R. Wilson,et al.  Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2 , 2016, Nature Communications.

[43]  C. Arrowsmith,et al.  Structure of the Catalytic Domain of EZH2 Reveals Conformational Plasticity in Cofactor and Substrate Binding Sites and Explains Oncogenic Mutations , 2013, PloS one.

[44]  Tim J. Wigle,et al.  EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity , 2015, ACS medicinal chemistry letters.

[45]  Q. Lei,et al.  ZLD1122, a novel EZH2 and EZH1 small molecular inhibitor, blocks H3K27 methylation and diffuse large B cell lymphoma cell growth , 2016 .

[46]  R. Copeland,et al.  The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat. , 2016, Journal of medicinal chemistry.

[47]  K. Helin,et al.  Transcriptional regulation by Polycomb group proteins , 2013, Nature Structural &Molecular Biology.

[48]  Jian Jin,et al.  Selective Inhibitors of Protein Methyltransferases , 2014, Journal of medicinal chemistry.

[49]  Kristian Helin,et al.  The Polycomb Group Protein Suz12 Is Required for Embryonic Stem Cell Differentiation , 2007, Molecular and Cellular Biology.

[50]  E. Chan,et al.  Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. , 2013, Chemistry & biology.

[51]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.